- Home
- CLDI vs RDHL Comparison
CLDI vs RDHL Comparison
Compare CLDI & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDI | RDHL |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 5.4M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | CLDI | RDHL |
|---|---|---|
| Price | $0.17 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 83.9K |
| Earning Date | 05-14-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.71 |
| 52 Week High | $7.32 | $3.31 |
Technical Indicators
Market Signals| Indicator | CLDI | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 52.93 |
| Support Level | $0.16 | $0.92 |
| Resistance Level | $0.30 | $1.07 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 21.00 | 46.76 |
Price Performance
Historical ComparisonAbout CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.